Parkinson's disease, trophic factors, and adrenal medullary chromaffin cell grafting: Basic and clinical studies

Brain Research Bulletin

Volumn 40, Issue 1, 1996, Pages 1-19

  Date, Isao ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Adrenal medulla; Dopamine; Neural transplantation; Neurotrophic factor

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACIDIC FIBROBLAST GROWTH FACTOR; BASIC FIBROBLAST GROWTH FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CHROMOGRANIN A; CILIARY NEUROTROPHIC FACTOR; DOPAMINE; EPIDERMAL GROWTH FACTOR; GANGLIOSIDE; NERVE GROWTH FACTOR; NEUROPEPTIDE; NEUROTROPHIC FACTOR; OXIDOPAMINE; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN B; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA;

ADRENAL MEDULLA; ADULT; AGED; AGING; ANIMAL CELL; ANIMAL MODEL; CELL TRANSPLANTATION; CHROMAFFIN CELL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; FETUS; GLIOMA CELL; GRAFT SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MOUSE; MULTICENTER STUDY; NERVE CELL PLASTICITY; NERVE GRAFT; NERVE REGENERATION; NONHUMAN; PARKINSON DISEASE; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; RAT; REVIEW;

EID: 0029873607     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/0361-9230(96)00010-X     Document Type: Review

References (223)

1. Acheson, A.; Barker, P. A.; Alderson, R. F.; Miller, F. D.; Murphy, R. A. Detection of brain-derived neurotrophic factor-like activity in fibroblasts and Schwann cells: Inhibition by antibodies to NGF. Neuron 7:265-275; 1991.
2. Aebischer, P.; Buchser, E.; Joseph, J. M.; Favre, J.; de Tribolet, N.; Lysaght, M.; Rudnick, S.; Goddard, M. Transplantation in humans of encapsulated xenogeneic cells without immunosuppression: A preliminary report. Transplantation 58:1275-1277; 1994.
3. Aebischer, P.; Tresco, P. A.; Sagen, J.; Winn, S. R. Transplantation of microencapsulated bovine chromaffin cells reduces lesion-induced rotational asymmetry in rats. Brain Res. 560:43-49; 1991.
4. Ahlskog, J. E.; Tyce, G. M.; Kelly, P. J.; van Heerden, J. A.; Stoddard, S. L.; Carmichael, S. W. Cerebrospinal fluid indices of blood-brain barrier permeability following adrenal-brain transplantation in patients with Parkinson's disease. Exp. Neurol. 105:152-161; 1989.
5. Allen, G. S.; Burns, R. S.; Tulipan, N. B.; Parker, R. A. Adrenal medullary transplantation to the caudate nucleus in Parkinson's disease. Arch. Neurol. 46:487-491; 1989.
6. Aloe, L.; Levi-Montalcini, R. Nerve growth factor-induced transformation of immature chromaffin cells in vitro into sympathetic neurons: Effect of antiserum to nerve growth factor. Proc. Natl. Acad. Sci. USA 76:1246-1250; 1979.
7. Annett, L. E.; Dunnett, S. B.; Martel, F. L.; Rogers, D. C.; Ridley, R. M.; Baker, H. F.; Marsden, C. D. A functional assessment of embryonic dopaminergic grafts in the marmoset. Prog. Brain Res. 82:535-542; 1990.
8. Apuzzo, M. L. J.; Neal, J. H.; Waters, C. H.; Appley, A. J.; Boyd, S. D.; Couldwell, W. T.; Wheelock, V. H.; Weiner, L. P. Utilization of unilateral and bilateral stereotactically placed adrenomedullary-striatal autografts in parkinsonian humans: Rationale, techniques, and observations. Neurosurgery 26:746-757; 1990.
9. Backlund, E.-O.; Granberg, P.-O.; Hamberger, B.; Knutsson, E.; Martensson, A.; Sedvall, G.; Seiger, A.; Olson, L. Transplantation of adrenal medullary tissue to striatum in parkinsonism: First clinical trials. J. Neurosurg. 62:169-173; 1985.
10. Bakay, R. A. E. Neurotransplantation: A clinical update. Acta Neurochir. 58(Suppl):8-16; 1993.
11. Bakay, R. A. E.; Allen, G. S.; Apuzzo, M.; Borges, L. F.; Bullard, D. E.; Ojemann, G. A.; Oldfield, E. H.; Penn, R.; Purvis, J. T.; Tindall, G. T. Preliminary report on adrenal medullary grafting from the American Association of Neurological Surgeons Graft Project. Prog. Brain Res. 82:603-610; 1990.
12. Ballarin, M.; Ernfors, P.; Lindefors, N.; Persson, H. Hippocampal damage and kainic acid injection induce a rapid increase in mRNA for BDNF and NGF in the rat brain. Exp.Neurol. 114:35-43; 1991.
13. Bankiewicz, K. S.; Oldfield, E. H.; Chiueh, C. C.; Doppman, J. L.; Jacobowitz, D. M.; Kopin, I. J. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 39:7-16; 1986.
14. Bankiewicz, K. S.; Plunkett, R. J.; Kopin, I. J.; Jacobowitz, D. M.; London, W. T.; Oldfield, E. H. Transient behavioral recovery in hemiparkinsonian primates after adrenal medullary allografts. Prog. Brain Res. 78:543-549; 1988.
15. Barker, C. F.; Billingham, R. E. Immunologically privileged sites. Adv. Immunol. 25:1-54; 1977.
16. Barker, R.; Dunnett, S. The biology and behaviour of intracerebral adrenal transplants in animals and man. Rev. Neurosci. 4:113-146; 1993.
17. Barker, R.; Dunnett, S. B. Ibotenic acid lesions of the striatum reduce drug-induced rotation in the 6-hydroxydopamine-lesioned rat. Exp. Brain Res. 101:365-374; 1994.
18. Barker, R. A.; Dunnett, S. B.; Fawcett, J. W. Immunohistochemical identification of rat adrenal cortical tissue in situ, in vitro and in intracerebral adrenal grafts. Exp. Neurol. 122:125-129; 1993.
19. Beck, K. D.; Valverde, J.; Alexi, T.; Poulsen, K.; Moffat, B.; Vandlen, R. A.; Rosenthal, A.; Hefti, F. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 373:339-341; 1995.
20. Becker, J. B.; Curran, E. J.; Freed, W. J. Adrenal medulla graft induced recovery of function in an animal model of Parkinson's disease: Possible mechanism of action. Can. J. Psychol. 44:293-310; 1990.
21. Becker, J. B.; Curran, E. J.; Freed, W. J.; Poltorak, M. Mechanism of action of adrenal medulla grafts: The possible role of peripheral and central dopamine systems. Prog. Brain Res. 82:499-507; 1990.
22. Becker, J. B.; Freed, W. J. Adrenal medulla grafts enhance functional activity of the striatal dopamine system following substantia nigra lesions. Brain Res. 462:401-406; 1988.
23. Becker, J. B.; Robinson, T. E.; Barton, P.; Sintov, A.; Sinden, R.; Levy, R. J. Sustained behavioral recovery from unilateral nigrostriatal damage produced by the controlled release of dopamine from a silicone polymer pellet placed into the denervated striatum. Brain Res. 508:60-64; 1990.
24. Berger, K.; Przedborski, S.; Cadet, J. L. Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. Brain Res. Bull. 26:301-307; 1991.
25. Bing, G.; Notter, M. F. D.; Hansen, J. T.; Gash, D. M. Comparison of adrenal medullary, carotid body and PC 12 cell grafts in 6-OHDA lesioned rats. Brain Res. Bull. 20:399-406; 1988.
26. Bing, G.; Notter, M. F. D.; Hansen, J. T.; Kellogg, C.; Kordower, J. H.; Gash, D. M. Cografts of adrenal medulla with C6 glioma cells in rats with 6-hydroxydopamine-induced lesions. Neuroscience 34:687-697; 1990.
27. Bjorklund, A.; Dunnett, S. B.; Stenevi, U.; Lewish, M. E.; Iversen, S. D. Reinnervation of the denervated striatum by substantia nigra transplants: Functional consequences as revealed by pharmacological and sensorimotor testing. Brain Res. 199:307-333; 1980.
28. Bjorklund, A.; Schmidt, R. H.; Stenevi, U. Functional reinnervation of the neostriatum in the adult rat by use of intraparenchymal grafting of dissociated cell suspensions from the substantia nigra. Cell Tissue Res. 212:39-45; 1980.
29. Bjorklund, A.; Stenevi, U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res. 177:555-560; 1979.
30. Blottner, D.; Westermann, R.; Grothe, C.; Bohlen, P.; Unsicker, K. Basic fibroblast growth factor in the adrenal gland. Eur. J. Neurosci. 1:471-478; 1989.
31. Bohn, M. C.; Cupit, L.; Marciano, F.; Gash, D.M. Adrenal medulla grafts enhance recovery of striatal dopaminergic fibers. Science 237:913-916; 1987.
32. Bradbury, M. W. B.; Westrop, R. J. Factors influencing exit of substances from cerebrospinal fluid into deep cervical lymph of the rabbit. J. Physiol. 339:519-534; 1983.
33. Brown, V. J.; Dunnett, S. B. Comparison of adrenal and fetal nigral grafts on drug induced rotation in rats with 6-OHDA lesions. Exp. Brain Res. 78:714-718; 1989.
34. Brundin, P.; Nilsson, O. G.; Gage, F. H.; Bjorklund, A. Cyclosporin A increases survival of cross-species intrastriatal grafts of embryonic dopamine-containing neurons. Exp. Brain Res. 60:204-208; 1985.
35. Burns, R. S.; Chiueh, C. C.; Markey, S. P.; Ebert, M. H.; Jacobowitz, D. M.; Kopin, I. J. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 80:4546-4550; 1983.
36. Cadet, J. L.; Katz, M.; Jackson-Lewis, V.; Fahn, S. Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: Behavioral and biochemical evidence. Brain Res. 476:10-15; 1989.
37. Cadet, J. L.; Last, R.; Kostic, V.; Przedborski, S.; Jackson-Lewis, V. Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen. Brain Res. Bull. 26:707-713; 1991.
38. Cadet, J. L.; Zhu, S. M. The intrastriatal 6-hydroxydopamine model of hemiparkinsonism: Quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic as well as postsynaptic nigrostriatal markers in the rat. Brain Res. 595:316-326; 1992.
39. Calne, D. B.; Langston, J. W.; Martin, W. R.; Stoessl, A. J.; Ruth, T. J.; Adam, M. J.; Pate, D. B.; Schulzer, M. Positron emission tomography after MPTP: Observations relating to the cause of Parkinson's disease. Nature 317:246-248; 1985.
40. CAPITCommittee; Langston, W. J.; Widner, H.; Goetz, C. G.; Brooks, D.; Fahn, S.; Freeman, T.; Watts, R. Core assessment program for intracerebral transplantation. Mov. Disord. 7:2-13; 1992.
41. Carman, L. S.; Gage, F. H.; Shults, C. W. Partial lesion of the substantia nigra: Relation between extent of lesion and rotational behavior. Brain Res. 553:275-283; 1991.
42. Casper, D.; Mytilineou, C.; Blum, M. EGF enhances the survival of dopamine neurons in rat embryonic mesencephalon primary cell culture. J. Neurosci. Res. 30:372-381; 1991.
43. Chiba, K.; Trevor, A.; Castagnoli, N. J. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120:574-578; 1984.
44. Claude, P.; Parada, I. M.; Gordon, K. A.; D'Amore, D. A.; Wagner, J. A. Acidic fibroblast growth factor stimulates adrenal chromaffin cells to proliferate and extend neuntes but is not a long term survival factor. Neuron 1:783-790; 1988.
45. Cohen, G. Oxyradical toxicity in catecholamine neurons. Neurotoxicology 5:77-82; 1984.
46. Cotzias, G. C.; Papavasiliou, P. S.; Gellene, R. Modification of parkinsonism: Chronic treatment with L-DOPA. N. Engl. J. Med. 280:385-389; 1969.
47. Cunningham, L. A.; Hansen, J. T.; Short, M. P.; Bohn, M. C. The use of genetically altered astrocyte to provide nerve growth factor to adrenal chromaffin cells grafted into the striatum. Brain Res. 561:192-202; 1991.
48. Cunningham, L. A.; Short, M. P.; Breakefield, X. O.; Bohn, M. C. Nerve growth factor released by transgenic astrocytes enhances the function of adrenal chromaffin cell grafts in a rat model of Parkinson's disease. Brain Res. 658:219-231; 1994.
49. Date, I.; Asari, S.; Ohmoto, T. Two-year follow-up study of a parkinsonian patient with severe motor fluctuations treated by cografts of adrenal medulla and peripheral nerve into bilateral caudate nuclei. Neurosurgery 37:515-519; 1995.
50. Date, I.; Felten, S. Y.; Felten, D. L. Exogenous GM1 gangliosides induce partial recovery of the nigrostriatal dopaminergic system in MPTP-treated young mice but not in aging mice. Neurosci. Lett. 106:282-286; 1989.
51. Date, L; Felten, S. Y.; Felten, D. L. Cografts of adrenal medulla with peripheral nerve enhance the survivability of transplanted adrenal chromaffin cells and recovery of the host nigrostriatal dopaminergic system in MPTP-treated young adult mice. Brain Res. 537:33-39; 1990.
52. Date, I.; Felten, D. L.; Felten, S. Y. Long-term effect of MPTP in the mouse brain in relation to aging: Neurochemical and immunocytochemical analysis. Brain Res. 519:266-276; 1990.
53. Date, I.; Felten, S. Y.; Felten, D. L. The nigrostriatal dopaminergic system in MPTP-treated mice shows more prominent recovery by syngeneic adrenal medullary graft than by allogeneic or xenogeneic graft. Brain Res. 545:191-198; 1991.
54. Date, L; Felten, S. Y.; Olschowka, J. A.; Felten, D. L. Limited recovery of striatal dopaminergic fibers by adrenal medullary grafts in MPTP-treated aging mice. Exp. Neurol. 107:197-207; 1990.
55. Date, I.; Kawamura, K.; Nakashima, H. Histological signs of immune reactions against allogeneic solid fetal neural grafts in the mouse cerebellum depend on the MHC locus. Exp. Brain Res. 73:15-22; 1988.
56. Date, I.; Kawamura, K.; Nakashima, H.; Ono, K.; Nishimoto, A. Intraparenchymal allografts in the mouse brain in relation to immunocytochemical identification of T lymphocyte subsets. Neurosci. Lett. 86:17-20; 1988.
57. Date, I.; Notter, M. F. D.; Felten, S. Y.; Felten, D. L. MPTP-treated young mice but not aging mice show partial recovery of the nigrostriatal dopaminergic system by stereotaxic injection of acidic fibroblast growth factor (aFGF). Brain Res. 526:156-160; 1990.
58. Date, I.; Hotter, M. F. D.; Felten, S. Y.; Felten, D. L. Stereotaxic injection of GD1a ganglioside induces limited recovery of striatal dopaminergic system in MPTP-treated aging mice. J. Neurosci. Res. 28:525-530; 1991.
59. Date, I.; Yoshimoto, Y.; Gohda, Y.; Furuta, T.; Asari, S.; Ohmoto, T. Long-term effects of cografts of pretransected peripheral nerve with adrenal medulla in animal models of Parkinson's disease. Neurosurgery 33:685-690; 1993.
60. Date, I.; Yoshimoto, Y.; Imaoka, T.; Miyoshi, Y.; Furuta, T.; Asari, S.; Ohmoto, T. Cografts of adrenal medulla with peripheral nerve for Parkinson's disease. Cell Transplant. 3, (Suppl 1):S47-S49; 1994.
61. Date, I.; Yoshimoto, Y.; Imaoka, T.; Miyoshi, Y.; Furuta, T.; Asari, S.; Ohmoto, T. Effect of host age upon the degree of nigrostriatal dopaminergic system recovery following cografts of adrenal medulla and pretransected peripheral nerve. Brain Res. 637:50-56; 1994.
62. Date, I.; Yoshimoto, Y.; Imaoka, T.; Miyoshi, Y.; Gohda, Y.; Furuta, T.; Asari, S.; Ohmoto, T. Enhanced recovery of the nigrostriatal dopaminergic system in MPTP-treated mice following intrastriatal injection of basic fibroblast growth factor in relation to aging. Brain Res. 621:150-154; 1993.
63. Date, I.; Yoshimoto, Y.; Miyoshi, Y.; Imaoka, T.; Furuta, T.; Asari, S.; Ohmoto, T. The influence of donor age on cografting of adrenal medulla with pretransected peripheral nerve. Brain Res. 624:233-238; 1993.
64. Date, I.; Furukawa, S.; Ohmoto, T. Increased nerve growth factor level in the distal stump of transected sciatic nerve in relation to aging and its application for neural grafting. Exp. Neurol. 130:168-171; 1994.
65. Date, I.; Imaoka, T.; Miyoshi, Y.; Ono, T.; Asari, S.; Ohmoto, T. Chromaffin cell survival and host dopaminergic fiber recovery in a patient with Parkinson's disease treated by cografts of adrenal medulla and pretransected peripheral nerve: A case report. J. Neurosurg. (in press).
66. Date, I.; Miyoshi, Y.; Imaoka, T.; Furuta, T.; Asari, S.; Ohmoto, T. Efficacy of pretransection of peripheral nerve for promoting the survival of cografted chromaffin cells and recovery of host dopaminergic fibers in animal models of Parkinson's disease. Neurosci. Res. 20:213-221; 1994.
67. Date. I.; Miyoshi, Y.; Imaoka, T.; Ono, T.; Furuta, T.; Asari, S.; Ohmoto, T. Chromaffin cell survival prolonged by nerve growth factor from pretransected sciatic nerve. Cell Transplant. 4(Suppl 1):s19-s21; 1995.
68. Date, I.; Ohmoto, T. Neural transplantation and trophic factors in Parkinson's disease: Special reference to chromaffin cell grafting, NGF support from pretransected peripheral nerve and encapsulated dopamine-secreting cell grafting. Exp. Neurol. (in press).
69. Date, I.; Ohmoto, T.; Imaoka, T.; Ono, T.; Hammang, J. P.; Francis, J.; Greco, C.; Emerich, D. F. Cografting with polymer-encapsulated human NGF-secreting cells enhances chromaffin cell survival and behavioral recovery in hemiparkinsonian rats. J. Neurosurg. (in press).
70. de Quidt, M. E.; Emson, P. C. Neuropeptide Y in the adrenal gland: Characterization, distribution and drug effects. Neuroscience 19:1011-1022; 1986.
71. Decombe, R.; Rivot, J. P.; Aunis, D.; Abrous, N.; Peschanski, M.; Herman, J. P. Importance of catecholamine release for the functional action of intrastriatal implants of adrenal medullary cells: Pharmacological analysis and in vivo electrochemistry. Exp. Neurol. 107:143-153; 1990.
72. Diamond, S. G.; Markham, C. H.; Rand, R. W.; Becker, D. P.; Treciokas, L. J. Four-year follow-up of adrenal-to-brain transplants in Parkinson's disease. Arch. Neurol. 51:559-563; 1994.
73. Doering, L. C. Peripheral nerve segments promote consistent long term survival of adrenal medulla transplants in the brain. Exp. Neurol 118:253-260; 1992.
74. Dubach, M. Adrenal medullary "ribbon" grafts in nonhuman primates: Transplant method. J. Neurosci. Methods 39:19-28; 1991.
75. Dubach, M.; German, D. C. Extensive survival of chromaffin cells in adrenal medulla "ribbon" grafts in the monkey neostriatum. Exp. Neurol. 110:167-180; 1990.
76. Dymecki, J.; Poltorak, M.; Freed, W. J. The degree of genetic disparity between donor and host correlates with survival of intraventricular substantia nigra grafts. Reg. Immunol. 3:17-22; 1990.
77. Emerich, D. F.; Winn, S. R.; Christenson, L.; Palmatier, M. A.; Gentile, F. T.; Sanberg, P. R. A novel approach to neural transplantation in Parkinson's disease: Use of polymer-encapsulated cell therapy. Neurosci. Biobehav. Rev. 16:437-447; 1992.
78. Engele, J.; Bohn, M. The neurotrophic effects of fibroblast growth factors on dopaminergic neurons in vitro are mediated by mesencephalic glia. J. Neurosci. 11:3070-3078; 1991.
79. Ewing, S. E.; Weber, R. J.; Zauner, A.; Plunkett, R. J. Recovery in hemiparkinsonian rats following intrastriatal implantation of activated leukocytes. Brain Res. 576:42-48; 1992.
80. Faraj, B. A.; Camp, V. M.; Watts, R. L. Effect of adrenal-caudate transplantation on CSF levels of salsolinol sulfate in patients with Parkinson's disease. J. Neural. Transm. 32(Suppl):481-484; 1990.
81. Fazzini, E.; Dwork, A. J.; Blum, C.; Burke, R.; Cote, L.; Goodman, R. R.; Jacobs, T. P.; Naini, A. B.; Pezzoli, G.; Pullman, S.; Solomon, R. A.; Truong, D.; Weber, C. J.; Fahn, S. Stereotaxic implantation of autologous adrenal medulla into caudate nucleus in four patients with parkinsonism. One-year follow-up. Arch. Neurol. 48:813-820; 1991.
82. Ferrari, G.; Minozzi, M.-C.; Toffano, G.; Leon, A.; Skaper, S. D. Basic fibroblast growth factor promotes the survival and development of mesencephalic neurons in culture. Dev. Biol. 133:140-147; 1989.
83. Fiandaca, M. S.; Kordower, J. H.; Hansen, J. T.; Jiao, S.-S.; Gash, D. M. Adrenal medullary autografts into the basal ganglia of cebus monkeys: Injury-induced regeneration. Exp. Neurol. 102:76-91; 1988.
84. Fine, A. Transplantation of adrenal tissue into the central nervous system. Brain Res. Rev. 15:121-133; 1990.
85. Fine, A.; Hunt, S. P.; Oertel, W. H.; Nomoto, M.; Chong, P. N.; Bond, A.; Waters, C.; Temlett, J. A.; Annett, L.; Dunnett, S. B.; Jenner, P.; Marsden, C. D. Transplantation of embryonic marmoset dopaminergic neurons to the corpus striatum of marmosets rendered parkinsonian by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Prog. Brain Res. 78:479-489; 1988.
86. Finklestein, S. P.; Fanning, P. J.; Caday, C. G. Increased levels of basic fibroblast growth factor (bFGF) following focal brain injury. Restor. Neurol. Neurosci. 1:387-394; 1990.
87. Forander, P.; Bjorklund, L.; Stromberg, I. Dose-dependent effects of recombinant human NGF on grafted adult adrenal medulla tissue. Exp. Neurol. 126:168-177; 1994.
88. Forno, L. S.; Langston, J. W. Unfavorable outcome of adrenal medullary transplant for Parkinson's disease. Acta Neuropathol. 81:691-694; 1991.
89. Forno, L. S.; Langsten, J. W.; DeLanney, L. E.; Irwin, I.; Ricaurte, G. A. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann. Neurol. 20:449-455; 1986.
90. Freed, W. J. Functional brain tissue transplantation: Reversal of lesion-induced rotation by intraventricular substantia nigra and adrenal medulla grafts, with a note on intracranial retinal grafts. Biol. Psychiatry 18:1205-1267; 1983.
91. Freed, W. J.; Cannon-Spoor, H.; Krauthamer, E. Intrastriatal adrenal medulla grafts in rats. J. Neurosurg. 65:664-670; 1986.
92. Freed, W. J.; Hoffer, B. J.; Olson, L.; Wyatt, R. J. Transplantation of catecholamine-containing tissues to restore the functional capacity of the damaged nigrostriatal system. In: Sladek, J. R.; Gash, D. M., eds. Neural transplants. New York: Plenum; 1984:373-406.
93. Freed, W. J.; Karoum, F.; Spoor, H. E.; Olson, L.; Morihisa, J.; Wyatt, R. J. Catecholamine content of intracerebral adrenal medulla grafts. Brain Res. 269:184-189; 1983.
94. Freed, W. J.; Morihisa, J. M.; Spoor, H. E.; Hoffer, B. J.; Olson, L.; Seiger, A.; Wyatt, R. J. Transplanted adrenal chromaffin cells in rat brain reduce lesion-induced rotational behavior. Nature 292:351-352; 1981.
95. Freed, W. J.; Poltorak, M.; Becker, J. B. Intracerebral adrenal medulla grafts: A review. Exp. Neurol. 110:139-166; 1990.
96. Frodin, M.; Gammeltoft, S. Insulin-like growth factors act synergistically with basic fibroblast growth factor and nerve growth factor to promote chromaffin cell proliferation. Proc. Natl. Acad. Sci. USA 91:1771-1775; 1994.
97. Gash, D. M.; Bresjanac, M.; Junn, F.; Zhang, Z. Trophic mechanisms mediating functional recovery following intrastriatal implantation. In: Dunnett, S. B.; Blorklund, A., eds. Functional neural transplantation. New York: Raven Press; 1994:139-156.
98. Gaumann, D. M.; Yaksh, T. L. Effects of hemorrhage and opiate antagonists on adrenal release of neuropeptides in cats. Peptides 9:393-405; 1987.
99. Goetz, C. G.; Olanow, C. W.; Koller, W. C.; Penn, R. D.; Cahill, D.; Morantz, R.; Stebbins, G.; Tanner, C. M.; Klawans, H. L.; Shannon, K. M.; Cornella, C. L.; Witt, T.; Cox, C.; Waxman, M.; Gauger, L. Multicenter study of autologous adrenal-medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N. Engl. J. Med. 320:337-341; 1989.
100. Goetz, C. G.; Stebbins, G. T. L; Klawans, H. L.; Koller, W. C.; Grossman, R. G.; Bakay, R. A. E.; Penn, R. D. United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: Presurgical, and 1- and 2-year follow-up. Neurology 41:1719-1722; 1991.
101. Goldsmith, H. S. Brain and spinal cord revascularization by omental transposition. Neurol. Res. 16:159-162; 1994.
102. Hadjiconstantinou, M.; Fitkin, J. G.; Dalia, A.; Neff, N. H. Epidermal growth factor enhances striatal dopaminergic parameters in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse. J. Neurochem. 57:479-482; 1991.
103. Hadjiconstantinou, M.; Rossetti, Z. L.; Paxton, R. C.; Neff, N. H. Administration of GM1 ganglioside restores the dopamine content in striatum after chronic treatment with MPTP. Neuropharmacology 25:1075-1077; 1986.
104. Hagg, T.; Varon, S. Ciliary neurotrophic factor (CNTF) prevents axotomy-induced degeneration of adult rat substantia nigra dopaminergic neurons. Soc. Neurosci. Abstr. 18:390; 1992.
105. Hansen, J. T.; Notter, M. F. D.; Okawara, S.-H.; Gash, D. M. Organization, fine structure and viability of the human adrenal medulla: Considerations for neural transplantation. Ann. Neurol. 24:599-609; 1988.
106. Hansen, J. T.; Sakai, K.; Greenamyre, J. T.; Moran, S. Sprouting of dopaminergic fibers from spared mesencephalic dopamine neurons in the unilateral partial lesioned rat. Brain Res. 670:197-204; 1995.
107. Hansson, H. A.; Dahlin, L. B.; Danielsen, N.; Fryklund, L.; Nachemson, A. K.; Polleryd, P.; Rozell, B.; Skottner, A.; Stemme, S.; Lundborg, G. Evidence indicating trophic important of IGF-1 in regenerating peripheral nerves. Acta Physiol. Scand. 126:609-614; 1986.
108. Hargraves, R.; Freed, W. J. Chronic intrastriatal dopamine infusions in rats with unilateral lesions of the substantia nigra. Life Sci. 40:959-966; 1987.
109. Heikkila, R. E.; Sonsalla, P. K. The use of the MPTP-treated mouse as an animal model of parkinsonism. Can. J. Neurol. Sci. 14(Suppl 3):436-469; 1987.
110. Herrera-Marschitz, M.; Stromberg, I.; Olsson, D.; Ungerstedt, U.; Olson, L. Adrenal medullary implants in the dopamine-denervated rat striatum: II. Acute behavior as a function of graft amount and location and its modulation by neuroleptics. Brain Res. 297:53-61; 1984.
111. Heumann, R.; Korsching, S.; Bandtlow, C. Changes of nerve growth factor synthesis in nonneuronal cells in response to sciatic nerve transection. J. Cell. Biol. 104:1623-1631; 1987.
112. Hirsch, E. C.; Duyckaerts, C.; Javoy-Agid, F.; Hauw, J.-J.; Agid, Y. Does adrenal graft enhance dopaminergic neurons recovery in Parkinson's disease? Ann. Neurol. 27:676-682; 1990.
113. Hoffer, B. J.; Hoffman, A.; Bowenkamp, K.; Huettl, P.; Hudson, J.; Martin, D.; Lin, L.-F. H.; Gerhardt, G. A. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 182:107-111; 1994.
114. Hudson, J. L.; van Home, C. G.; Stromberg, I.; Brock, S.; Clayton, J.; Masserano, J.; Hoffer, B. J.; Gerhardt, G. A. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res. 626:167-174; 1993.
115. Hurtig, H.; Joyce, J.; Sladek, J. R.; Trojanowski, J. Q. Postmortem analysis of adrenal medulla to caudate autograft in a patient with Parkinson's disease. Ann. Neurol. 25:607-614; 1989.
116. Hylden, J. L. K.; Wilcox, G. L. Pharmacological characterization of substance P-induced nociception in mice: Modulation by opioid and noradrenergic agonists at the spinal level. J. Pharmacol. Exp. Ther. 226:398-404; 1983.
117. Hyman, C.; Hofer, M.; Barde, Y.-A.; Juhasz, M.; Yancopoulos, G. D.; Squinto, S. P.; Lindsay, R. M. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350:230-232; 1991.
118. Isono, M.; Braun, D.; Poltorak, M.; Freed, W. J. Immunological reactions following intracerebroventricular transplantation of adrenal medulla. Restor. Neurol. Neurosci. 6:89-95; 1994.
119. Isono, M.; Poltorak, M.; Kulaga, H.; Adams, A. J.; Freed, W. J. Certain host-donor rat strain combinations do not reject brain allografts after systemic sensitization. Exp. Neurol. 122:48-56; 1993.
120. Jankovic, J.; Grossman, R.; Goodman, C.; Pirozzolo, F.; Schneider, L.; Zhu, Z.; Scardino, P.; Garber, A. J.; Jhingran, S. G.; Martin, S. Clinical, biochemical, and neuropathologic findings following transplantation of adrenal medulla to the caudate nucleus for treatment of Parkinson's disease. Neurology 39:1227-1234; 1989.
121. Jousselin-Hosaja, M. Effects of transplantation on mouse adrenal chromaffin cells. J. Endocrinol. 116:149-153; 1988.
122. Jousselin-Hosaja, M. Ultrastructural evidence for the development of adrenal medullary grafts in the brain. Exp. Brain Res. 73:637-647; 1988.
123. Jousselin-Hosaja, M. A descriptive and quantitative morphometric study of long-term mouse adrenal medulla grafts implanted into the putamen: Effect of nerve growth factor injected at grafting. Brain Res. 627:275-286; 1993.
124. Jousselin-Hosaja, M.; Mailly, P.; Tsuji, S. Mouse adrenal chromaffin cells can transform to neuron-like cholinergic phenotypes after being grafted into the brain. Cell Tissue Res. 274:199-205; 1993.
125. Kaakkola, S.; Teravainen, H. Animal models of Parkinsonism. Pharmacol. Toxicol. 67:95-100; 1990.
126. Kearns, C. M.; Gash, D. M. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 672:104-111; 1995.
127. Kelly, P. J.; Ahlskog, J. E.; Heerden, J. A.; Carmichael, S. W.; Stoddard, S. L. Adrenal medullary autograft transplantation into the striatum of patients with Parkinson's disease. Mayo Clin. Proc. 64:282-290; 1989.
128. Kish, S. J.; Shannak, K.; Hornykiewicz, O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: Pathophysiologic and clinical implication. N. Engl. J. Med. 318:876-880; 1988.
129. Knusel, B.; Michel, P. P.; Schwaber, J. S.; Hefti, F. Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors I and II. J. Neurosci. 10:558-570; 1990.
130. Kopin, I. J.; Markey, S. P. MPTP toxicity: Implications for research in Parkinson's disease. Ann. Rev. Neurosci. 11:81-96; 1988.
131. Kordower, J. H.; Cochran, E.; Penn, R. D.; Goetz, C. G. Putative chromaffin cell survival and enhanced host-derived TH-fiber innervation following a functional adrenal medulla autograft for Parkinson's disease. Ann. Neurol. 29:405-412; 1991.
132. Kordower, J. H.; Fiandaca, M. S.; Notter, M. F. D.; Hansen, J. T.; Gash, D. M. NGF-like trophic support from peripheral nerve for grafted rhesus adrenal chromaffin cells. J. Neurosurg. 73:418-428; 1990.
133. Krieglstein, K.; Unsicker, K. Transforming growth factor-β promotes survival of midbrain dopaminergic neurons and protects them against N-methyl-4-phenylpyridinium ion toxicity. Neuroscience 63:1189-1196; 1994.
134. Kroin, J. S.; Kao, L. C.; Zhang, T. J.; Penn, R. D.; Klawans, H. L.; Carvey, P. M. Dopamine distribution and behavioral alterations resulting from dopamine infusion into the brain of the lesioned rat. J. Neurosurg. 74:105-111; 1991.
135. Kuraishi, Y.; Harada, Y.; Takagi, H. Noradrenaline regulation of pain-transmission in the spinal cord mediated by alpha-adrenoreceptors. Brain Res. 174:333-336; 1979.
136. Lachmund, A.; Gehrke, D.; Krieglstein, K.; Unsicker, K. Trophic factors from chromaffin granules promote survival of peripheral and central nervous system neurons. Neuroscience 62:361-370; 1994.
137. Langston, J. W.; Ballard, P. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Implications for treatment and the pathogenesis of Parkinson's disease. Can. J. Neurol. Sci. 11:160-165; 1984.
138. Langston, J. W.; Ballard, P.; Tetrud, J. W.; Irwin, I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980; 1983.
139. Ledeen, R. W. Ganglioside structures and distribution: Are they localized at the nerve ending? J. Supramolec. Struct. 8:1-71; 1978.
140. Ledeen, R. W. Biology of gangliosides: Neuritogenic and neuronotrophic properties. J. Neurosci. Res. 12:147-159; 1984.
141. Lin, L.-F. H.; Doherty, D. H.; Lile, J. D.; Bektesh, S.; Collins, F. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132; 1993.
142. Lindvall, O.; Backlund, E.-O.; Farde, L.; Sedvall, G.; Freedman, R.; Hoffer, B. Transplantation in Parkinson's disease: Two cases of adrenal medullary grafts to the putamen. Ann. Neurol. 22:457-468; 1987.
143. Livett, G.; Dean, D. M.; Whelan, L. G.; Udenfriend, S.; Rossier, J. Co-release of enkephalin and catecholamines from cultured adrenal chromaffin cells. Science 225:734-737; 1981.
144. Lopez-Lozano, J. J.; Bravo, G.; Abascal, J. Grafting of perfused adrenal medullary tissue into the caudate nucleus of patients with Parkinson's disease. J. Neurosurg. 75:234-243; 1991.
145. Lopez-Lozano, J. J.; Bravo, G.; Abascal, J.; Brera, B.; Santos, J.; Gomez-Angulo, C. Co-transplantation of peripheral nerve and adrenal medulla in Parkinson's disease. Lancet 339:430; 1992.
146. Lopez-Lozano, J. J.; Brera, B.; Abascal, J.; Bravo, G. Preparation of adrenal medullary tissue for transplantation in Parkinson's disease: A new procedure. J. Neurosurg. 71:452-454; 1989.
147. Madrazo, I.; Drucker-Colin, R.; Diaz, V.; Martinez-Mata, J.; Torres, C.; Becerri, J. J. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. N. Engl. J. Med. 316:831-834; 1987.
148. Madrazo, L; Franco-Bourland, R.; Aguilera, M.; Ostrosky-Solis, F.; Cuevas, C.; Castrejon, H.; Magallon, E.; Mardrazo, M. Development of human neural transplantation. Neurosurgery 29:165-177; 1991.
149. Manthorpe, M.; Skaper, S. D.; Williams, L. R.; Varon, L. Purification of adult rat sciatic nerve ciliary neuronotrophic factor. Brain Res. 367:282-286; 1986.
150. Mason, D. W.; Charlton, H. M.; Jones, A. J.; Lavy, C. B. D.; Puklavec, M.; Simmonds, S. J. The fate of allogeneic and xenogeneic neuronal tissue transplanted into the third ventricle of rodents. Neuroscience 19:685-694; 1986.
151. Morihisa, J. M.; Nakamura, R. K.; Freed, W. J.; Mishkin, M.; Wyatt, R. J. Adrenal medulla grafts survive and exhibit catecholamine specific fluorescence in the primate brain. Exp. Neurol. 84:643-653; 1984.
152. Nakashima, H.; Kawamura, K.; Date, I. Immunological reaction and blood-brain barrier in mouse-to-rat cross-species neural graft. Brain Res. 475:232-243; 1988.
153. Nicholas, M. K.; Antel, J. P.; Stefansson, K.; Arnason, B. G. W. Rejection of fetal neocortical neural transplants by H-2 incompatible mice. J. Immunol. 139:2275-283; 1987.
154. Niijima, K.; Chalmers, G. R.; Peterson, D. A.; Fisher, L. J.; Patterson, P. H.; Gage, F. H. Enhanced survival and neuronal differentiation of adrenal chromaffin cells cografted into the striatum with NGF-producing fibroblasts. J. Neurosci. 15:1180-1194; 1995.
155. Nikkhah, G.; Odin, P.; Smits, A.; Tingstrom, A.; Othberg, A.; Brundin, P.; Funa, K.; Lindvall, O. Platelet-derived growth factor promotes survival of rat and human mesencephalic dopaminergic neurons in culture. Exp. Brain Res. 92:516-523; 1993.
156. Nishino, H.; Ono, T.; Shibata, R.; Kawamata, S.; Watanabe, H.; Shiosaka, S.; Tohyama, M.; Karadi, Z. Adrenal medullary cells transmute into dopaminergic neurons in dopamine-depleted rat caudate and ameliorate motor disturbances. Brain Res. 445:325-337; 1988.
157. Nishino, H.; Ono, T.; Takahashi, J.; Kimura, M.; Shiosaka, S.; Yamasaki, H.; Hatanaka, H.; Tohyama, M. The formation of new neuronal circuit between transplanted nigral dopamine neurons and nonimmunoreactive axon terminals in the host rat caudate nucleus. Neurosci. Lett. 64:13-16; 1986.
158. Olson, L.; Backlund, E.-O.; Ebendal, T.; Freedman, R.; Hamberger, B.; Hansson, P.; Hoffer, B.; Lindblom, U.; Meyerson, B.; Stromberg, I.; Sydou, O.; Seiger, A. Intraputaminal infusion of nerve growth factor to support adrenal medullary autografts in Parkinson's disease. Arch. Neurol. 48:373-381; 1991.
159. Olson, L.; Backman, L.; Eriksdotter-Jonhagen, M.; Hoffer, B.; Humpel, C.; Freedman, R.; Giacobini, M.; Meyerson, B.; Nordberg, A.; Seiger, A.; Stromberg, I.; Sydow, O.; Tomac, A.; Trok, K.; Winblad, B. Role of growth factors in degeneration and regeneration in the CNS; clinical experiences with NGF in Parkinson's and Alzheimer's diseases. J. Neurol. 241:S12-S15; 1994.
160. Olson, L.; Seiger, A.; Freedman, R.; Hoffer, B. Chromaffin cells can innervate brain tissue: Evidence from intraocular double grafts. Exp. Neurol. 70:414-426; 1980.
161. Ortega, J. D.; Pappas, G. D. Short-term immunosuppression enhances long-term survival of bovine chromaffin cell xenografts in rat CNS. Cell Transplant. 1:33-41; 1992.
162. Otto, D.; Unsicker, K. Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice. J. Neurosci. 10:1912-1921; 1990.
163. Patel-Vaidya, U.; Wells, M. R.; Freed, W. J. Survival of dissociated adrenal chromaffin cells of rat and monkey transplanted into rat brain. Cell Tissue Res. 240:281-285; 1985.
164. Penn, R. D.; Goetz, C. G.; Tanner, C. M.; Klawans, H. L.; Shannon, K. M.; Comella, C. L.; Witt, T. R. The adrenal medullary transplant operation for Parkinson's disease: Clinical observation in five patients. Neurosurgery 22:999-1004; 1988.
165. Perese, D. A.; Ulman, J.; Viola, J.; Ewing, S. E.; Bankiewicz, K. S. A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Res. 494:285-293; 1989.
166. Peterson, D. I.; Price, M. L.; Small, C. S. Autopsy findings in a patient who had an adrenal-to-brain transplant for Parkinson's disease. Neurology 39:235-238; 1989.
167. Plunkett, R. J.; Bankiewicz, K. S.; Cummis, A. C. Long-term evaluation of hemiparkinsonian monkeys after adrenal autografting or cavitation alone. J. Neurosurg. 73:918-926; 1990.
168. Poltorak, M.; Freed, W. J. BN rats do not reject F344 brain allografts even after systemic sensitization. Ann. Neurol. 29:377-388; 1991.
169. Rafael, H.; Moromizato, P.; Espinoza, M.; Ayulo, V.; Gonzalez-Portillo, M. Transplantation of adrenal medulla and omentum to the putamen by a transinsular pathway for Parkinson's disease. Neurosurgery 28:481; 1991.
170. Rosenstein, J. M. Adrenal medulla grafts produce blood-brain barrier dysfunction. Brain Res. 414:192-196; 1987.
171. Sachs, C.; Jonsson, G. Mechanism of action of 6-hydroxydopamine. Biochem. Pharmacol. 24:1-8; 1975.
172. Sagen, J. Chromaffin cell transplants for alleviation of chronic pain. ASAIO J. 38:24-28; 1992.
173. Sakai, K.; Date, I.; Yoshimoto, Y.; Arisawa, T.; Nakashima, H.; Furuta, T.; Asari, S.; Ohmoto, T. The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents. Brain Res. 565:167-170; 1991.
174. Sakai, K.; Yoshimoto, Y.; Date, I. The effect of a short-course treatment with FK506 on the survivability of rat-to-mouse cross-species neural graft. Restor. Neurol. Neurosci. 5:131-139; 1993.
175. Scatton, B.; Javoy-Agid, F.; Rouquier, L.; Dubois, B.; Agid, Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 275:321-328; 1983.
176. Schneider, J. S. Effects of age on GM1 ganglioside-induced recovery of concentrations of dopamine in the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. Neuropharmacology 31:185-192; 1992.
177. Schueler, S. B.; Ortega, J. D.; Sagen, J.; Kordower, J. H. Robust survival of isolated bovine adrenal chromaffin cells following intrastriatal transplantation: A novel hypothesis of adrenal graft viability. J. Neurosci. 13:4496-4510; 1993.
178. Schueler, S. B.; Sagen, J.; Pappas, G. D.; Kordower, J. H. Long-term viability of isolated bovine adrenal medullary chromaffin cells following intrastriatal transplantation. Cell Transplant. 4:55-64; 1995.
179. Schultzberg, M.; Andersson, C.; Unden, A.; Troye-Bomberg, M.; Svenson, S. B.; Bartfai, T. Interleukin-1 in adrenal chromaffin cells. Neuroscience 30:805-810; 1989.
180. Schwartz, J. P.; Chuang, D.-M.; Costa, E. Increase in nerve growth factor content of C6 glioma cells by the activation of a β-adrenergic receptor. Brain Res. 137:369-375; 1977.
181. Shults, C. W.; O'Connor, D. T.; Baird, A.; Hill, R.; Goetz, C. G.; Watts, R. L.; Klawans, H. L.; Carvey, P. M.; Bakay, R. A.; Gage, F. H. Clinical improvement in parkinsonian patients undergoing adrenal to caudate transplantation is not reflected by chromogranin A or basic fibroblast growth factor in ventricular fluid. Exp. Neurol. 111:276-281; 1991.
182. Silani, V.; Falini, A.; Strada, O.; Pizzuti, A.; Pezzoli, G.; Motti, E. D. F.; Vegeto, A.; Scarlato, G. Effect of nerve growth factor in adrenal autografts in parkinsonism. Ann. Neurol. 27:341-342; 1990.
183. + into the nigrostriatal dopamine pathway: I. Behavioural, neurochemical and histological characterization of the lesion. Neuroscience 27:117-128; 1988.
184. Smith, R. D.; Zhang, Z.; Kurlan, R.; McDermott, M.; Gash, D. M. Developing a stable bilateral model of parkinsonism in rhesus monkeys. Neuroscience 52:7-16; 1993.
185. Spina, M. B.; Squinto, S. P.; Miller, J.; Lindsay, R. M.; Hyman, C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: Involvement of the glutathione system. J. Neurochem. 59:99-106; 1992.
186. Springer, J. Nerve growth factor receptors in the central nervous system. Exp. Neurol. 102:354-365; 1988.
187. Stemple, D. L.; Mahanthappa, H. K.; Anderson, D. J. Basic FGF induces neuronal differentiation, cell division and NGF dependence in chromaffin cells: A sequence of events in sympathetic development. Neuron 1:517-525; 1988.
188. Stoddard, S. L.; Ahlskog, J. E.; Kelly, P. J.; Tyce, G. M.; van Heerden, J. A.; Zinsmeister, A. R.; Carmichael, S. W. Decreased adrenal medullary catecholamines in adrenal transplanted parkinsonian patients compared to nephrectomy patients. Exp. Neurol. 104:218-222; 1989.
189. Stoddard, S. L.; Tyce, G. M.; Ahlskog, J. E.; Zinsmeister, A. R.; Nelson, D. K.; Carmichael, S. W. Decreased levels of [Met]enkephalin, neuropeptide Y, substance P, and vasoactive intestinal peptide in parkinsonian adrenal medulla. Exp. Neurol. 114:23-27; 1991.
190. Strada, O.; Hirsch, E. C.; Javoy-Agid, P.; Duyckaerts, C.; Hauw, J.-J.; Agid, Y. Low affinity nerve growth factor receptor, adrenal transplant and Parkinson's disease. J. Neurol. Sci. 120:33-37; 1993.
191. Stromberg, I.; Herrera-Marschitz, M.; Hultgren, L.; Ungerstedt, U.; Olson, L. Adrenal medullary implants in the dopamine-denervated rat striatum: I. Acute catecholamine levels in grafts and host caudate as determined by HPLC-electrochemistry and fluorescence histochemical image analysis. Brain Res. 297:41-51; 1984.
192. Stromberg, I.; Herrera-Marschitz, M.; Ungerstedt, U.; Ebendal, T.; Olson, L. Chronic implants of chromaffin tissue into the dopamine-denervated striatum. Effects of NGF on graft survival, fiber growth and rotational behavior. Exp. Brain Res. 60:335-349; 1985.
193. Takashima, H.; Poltorak, M.; Becker, J. B.; Freed, W. J. Effects of adrenal medulla grafts on plasma catecholamines and rotational behavior. Exp. Neurol. 118:24-34; 1992.
194. Taniuchi, M.; Clark, H. B.; Johnson, E. M. Induction of nerve growth factor receptor in Schwann cells after axotomy. Proc. Natl. Acad. Sci. USA 83:4094-4098; 1986.
195. Tischler, A. S.; Perlman, R. L.; Nunnemacher, G.; Morse, R. A.; Delellis, A.; Wolfe, H. J.; Sheard, B. E. Long-term effects of dexamethasone and NGF on adrenal chromaffin cells cultured from young adult rats. Cell Tissue Res. 225:525-542; 1982.
196. Tokiwa, M. A.; Gaspar, E. M.; Doering, L. C. CNTF is superior to NGF as a survival enhancement factor for adrenal medulla cells in vitro. NeuroReport 5:549-552; 1994.
197. Tomac, A.; Lindqvist, E.; Lin, L.-F. H.; Ogren, S. O.; Young, D.; Hoffer, B. J. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373:335-339; 1995.
198. Tresco, P. A.; Winn, S. R.; Aebischer, P. Polymer encapsulated neurotransmitter secreting cells: Potential treatment for Parkinson's disease. ASAIO J. 38:17-23; 1992.
199. Tsui, J. K.; Peppard, R. F.; Petruk, K. C.; Allen, G.; Burns, S.; Caine, D. B. Decreased efficacy of levodopa with carbidopa in parkinsonian patients after adrenal to caudate implants. Neurology 40:845-846; 1990.
200. Tyce, G. M.; Ahlskog, J. E.; Carmichael, S. W.; Chritton, S. L.; Stoddard, S. L.; van Heerden, J. A.; Yaksh, T. L.; Kelly, P. J. Catecholamines in CSF, plasma, and tissue after autologous transplantation of adrenal medulla to the brain in patients with Parkinson's disease. J. Lab. Clin. Med. 114:185-192; 1989.
201. Ungerstedt, U. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. 82(Suppl 367):69-93; 1971.
202. Ungerstedt, U. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behavior. Acta Physiol. Scand. 367(Suppl):49-68; 1971.
203. Unsicker, K. The trophic cocktail made by adrenal chromaffin cells. Exp. Neurol. 123:167-173; 1993.
204. Unsicker, K.; Krisch, B.; Otten, U.; Thoenen, H. Nerve growth factor-induced fiber outgrowth from isolated rat adrenal chromaffin cells: Impairment by glucocorticoids. Proc. Natl. Acad. Sci. USA 75:3498-3502; 1978.
205. Unsicker, K.; Skaper, S. D.; Varon, S. Developmental changes in the responses of rat chromaffin cells to neuronotrophic and neurite-promoting factors. Dev. Biol. 111:425-433; 1985.
206. Unsicker, K.; Stogbauer, F. Screening of adrenal medullary neuropeptides for putative neurotrophic effects. Int. J. Dev. Neurosci. 10:171-179; 1992.
207. Vanier, M. T.; Holm, M.; Ohman, R.; Svennerholm, L. Developmental profiles of gangliosides in human and rat brain. J. Neurochem. 18:581-592; 1971.
208. Wang, J.; Bankiewicz, K. S.; Plunkett, R. J.; Oldfield, E. H. Intrastriatal implantation of interleukin-1. J. Neurosurg. 80:484-490; 1994.
209. Waters, C.; Itabashi, H. H.; Apuzzo, L. J.; Weiner, L. P. Adrenal to caudate transplantation - Postmortem study. Mov. Disord. 5:248-250; 1990.
210. Waters, C. H.; Apuzzo, M. L. J.; Neal, J. H.; Weiner, L. P. Long-term follow-up of adrenal medullary transplantation for Parkinson's disease. J. Geriatr. Psychiatry Neurol. 5:35-39; 1992.
211. Watts, N. B.; Clark, R. V.; Watts, R. L.: Graham Jr, S. D.; Bakay, R. A. E. Changes in endocrine function after adrenal medullary transplantation to the central nervous system. J. Clin. Endocrinol. Metab. 70:773-776; 1990.
212. Watts, R. L.; Mandir, A. S.; Bakay, R. A. E. Intrastriatal cografts of autologous adrenal medulla and sural nerve in MPTP-induced parkinsonian macaques: Behavioral and anatomical assessment. Cell Transplant. 4:27-38; 1995.
213. Westermann, R.; Hardung, M.; Meyer, D. K.; Ekhrhard, P.; Otten, U.; Unsicker, K. Neurotrophic factors released by C6 glioma cells. J. Neurochem. 50:1747-1758; 1988.
214. Westermann, R.; Johannsen, M.; Unsicker, K.; Grothe, C. Basic fibroblast growth factor (bFGF) immunoreactivity is present in chromaffin granules. J. Neurochem. 55:285-292; 1990.
215. Winkler, H.; Apps, D. K.; Fischer-Colbrie, R. The molecular function of adrenal chromaffin granules: Established facts and unresolved topics. Neuroscience 18:261-290; 1986.
216. Winkler, H.; Fischer-Colbrie, R. The chromogranins A and B: The first 25 years and future perspectives. Neuroscience 49:497-528; 1992.
217. Winnie, A. P.; Pappas, G. D.; Gupta, T. K. D.; Wang, H.; Ortega, J. D.; Sagen, J. Subarachnoid adrenal medullary transplants for terminal cancer pain. Anesthesiology 79:644-653; 1993.
218. Winningham-Major, F.; Staecker, J. L.; Barger, S. W.; Coats, S.; Van Eldik, L. J. Neurite extension and neuronal survival activities of recombinant S100 β proteins that differ in the content and position of cysteine residues. J. Biol. Chem. 263:7830-7837; 1988.
219. Wurtman, R. J.; Pohorecky, L. A.; Baliga, B. S. Adrenocortical control of the biosynthesis of epinephrine and proteins in the adrenal medulla. Pharmacol. Rev. 24:411-426; 1972.
220. Yahr, M. D.; Duvoisin, R. C.; Shear, M. J.; Barrett, R. E.; Hoehn, M. M. Treatment of parkinsonism with levodopa. Arch. Neurol. 21:343-354; 1969.
221. Yamaguchi, F.; Itano, T.; Miyamoto, O. Increase of extracellular insulin-like growth factor I (IGF-I) concentration following electrolytical lesion in rat hippocampus. Neurosci. Lett. 128:273-276; 1991.
222. Zhou, J.; Date, I.; Sakai, K.; Yoshimoto, Y.; Furuta, T.; Asari, S.; Ohmoto, T. Suppression of immunorejection against rat fetal dopaminergic neurons in a mouse brain by 15-deoxyspergualin, Brain Res. 621:155-160; 1993.
223. Zhou, J.; Date, I.; Sakai, K.; Yoshimoto, Y.; Furuta, T.; Asari, S.; Ohmoto, T. Xenogeneic dopaminergic grafts reverse behavioral deficits induced by 6-OHDA in rodents: Effect of 15-deoxyspergualin treatment. Neurosci. Lett. 163:81-84; 1993.